Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Rhea-AI Summary

Tenax Therapeutics (Nasdaq: TENX) has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference in Miami, FL. The company, which specializes in developing treatments for cardiovascular and pulmonary diseases with high unmet medical need, will be featured in a fireside chat presentation.

The presentation is scheduled for March 10, 2025, at 3:40pm ET and will include participation from Chris Giordano, President & Chief Executive Officer, and Dr. Stuart Rich, Chief Medical Officer. The Phase 3 development-stage pharmaceutical company will make both live and archived versions of the presentation available through their investor relations webpage.

CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12, 2025, in Miami, FL.

Details of presentation:

Format: Fireside Chat

Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, MD, Chief Medical Officer

Date and Time: March 10, 2025, at 3:40pm ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan, which it has prioritized in the near term. Tenax Therapeutics also may resume developing its unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Merrill Barrett
Argot Partners
tenax@argotpartners.com

FAQ

When is Tenax Therapeutics (TENX) presenting at the Leerink Partners 2025 Conference?

Tenax Therapeutics is presenting on March 10, 2025, at 3:40pm ET during the Leerink Partners 2025 Global Healthcare Conference in Miami, FL.

Who will represent TENX at the Leerink Partners 2025 Healthcare Conference?

Chris Giordano, President & CEO, and Dr. Stuart Rich, Chief Medical Officer, will represent Tenax Therapeutics at the conference.

What type of presentation will TENX deliver at the Leerink Partners Conference?

Tenax Therapeutics will participate in a fireside chat format presentation at the conference.

How can investors access TENX's Leerink Partners Conference presentation?

Both live and archived versions of the presentation will be accessible through Tenax Therapeutics' investor relations webpage.

What is the current development stage of Tenax Therapeutics (TENX)?

Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focusing on cardiovascular and pulmonary diseases with high unmet medical need.